Raphael Phinicarides

Dr. Raphael Phinicarides


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DKDominika Kanschik
Dominika Kanschik
APAmin Polzin
Amin Polzin
HHHoutan Heidari
Houtan Heidari
LDLisa Dannenberg
Lisa Dannenberg
Raphael PhinicaridesRaphael Phinicarides
Raphael Phinicarides
SAShazia Afzal
Shazia Afzal
Background: An accurate device sizing for percutaneous left atrial appendage closure (LAAC) can be challenging. Intraprocedural automated LAA evaluation by transoesophageal echocardiography (TEE) based on an artificial intelligence-assisted 3D model may facilitate sizing and prediction of C-arm angulation for device implantation in a one-stop-shop procedure. This study aimed to evaluate the feasibility and accuracy of automated echocardiographic LAA sizing based on a patient-specific 3D heart model prototype in real-time. Methods: A prospective monocentric study was conducted in 66 patients who underwent LAAC with the Amulet device. All major LAA morphologies were represented. Preprocedural multidetector computed tomography (MSCT) measurements and intraprocedural TEE and angiography measurements of the ostium, landing zone, and C-arm angulation were compared with the 3D heart model measurements. Results: The procedure achieved a 100% success rate. The measurements for the maximum diameter of the ostium in the 3D heart model were not significantly different from those obtained via angiography, TEE, and MSCT. Specifically, the maximum diameter of the landing zone did not differ significantly compared to TEE and angiographic measurements (20.90 ± 3.42 mm vs. 20.96 ± 4.81 mm, p = 0.563; compared to 21.20 ± 3.90 mm, p = 0.291). However, these measurements were significantly smaller than the average MSCT measurements (18.30 ± 2.68 mm vs. 21.03 ± 4.34 mm, p < 0.001). Additionally, the predicted implantation angles showed no significant differences between the 3D heart model and MSCT. Conclusions: The intraprocedural application of this prototype is both safe and feasible. The measurements obtained from the 3D heart model were consistent with those from TEE and angiography, although discrepancies were noted when compared to MSCT measurements. Notably, the predicted implantation angles demonstrated strong agreement with MSCT, further supporting the prototype’s efficacy in clinical settings.

Verified
Journal Article
Open access
PDF file
Raphael PhinicaridesRaphael Phinicarides
Raphael Phinicarides
KBKira Lisanne Berning
Kira Lisanne Berning
HHHoutan Heidari
Houtan Heidari
DKDominika Kanschik
Dominika Kanschik
APAmin Polzin
Amin Polzin
SAShazia Afzal
Shazia Afzal
(1) Background: Transesophageal echocardiography (TEE) is the gold standard for diagnosing patent foramen ovale (PFO) in cryptogenic ischemic stroke. However, false-positive diagnoses remain clinically relevant, exposing patients to unnecessary invasive procedures. (2) Methods: We retrospectively analyzed 346 patients with cryptogenic ischemic stroke who underwent TEE for PFO from 2012–2021. PFO was confirmed in 326 patients (94.2%), whereas 20 patients (5.8%, 95% CI 3.6–8.9%) were adjudicated as false positives during subsequent cardiac catheterization (intracardiac echocardiography, angiography, and inability to cross the interatrial septum). Univariable and multivariable logistic regression identified predictors of diagnostic accuracy. (3) Results: False-positive cases were associated with less frequent use of the mid-esophageal bicaval view (50% vs. 87%, p < 0.001) and absence of early bubble transit. Multivariable analysis confirmed the mid-esophageal bicaval view as an independent predictor of accurate diagnosis (OR 5.23, 95% CI 2.11–12.9, p < 0.001). (4) Conclusion: False-positive PFO diagnoses occur in ~6% of patients referred for closure. Three quality criteria—mid-esophageal aortic valve short axis, bicaval view, and bubble test with x-plane analysis—may improve diagnostic reliability. These hypothesis-generating findings require prospective validation and alignment with ASE/ESC guidelines to reduce unnecessary invasive procedures.

9 November 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Raphael PhinicaridesRaphael Phinicarides
Raphael Phinicarides
CQC Q Quast
C Q Quast
SAS A Afzal
S A Afzal
VVVerena Veulemans
Verena Veulemans
KKK K Klein
K K Klein
APA P Polzin
A P Polzin
Background/Introduction: Dynamic Coronary Roadmap (DCR) is a software tool that creates a real-time dynamic coronary artery overlay on the fluoroscopic image. Its efficacy in significantly reducing contrast medium use during percutaneous coronary interventions (PCI) has already been shown. Purpose: The purpose of this study is to investigate whether the positive effects of DCR persist irrespective of the investigator’s experience level. Methods: In this sub-analysis of a monocentric, open-label, randomized trial, 130 patients with hemodynamically relevant coronary type A and B lesions were randomized (1:1 ratio) and conducted with or without DCR software. PCI was randomly allocated and performed by an investigator with high (A) or medium (B) experience level. Results: Overall, the primary endpoint contrast medium use was significantly reduced by both investigators in the +DCR group (Investigator A: –DCR 68.62 +/- 23.86ml vs. +DCR 43.39 +/- 21.91ml; Investigator B: –DCR 70.80 +/- 31.77ml vs. +DCR 29.46 +/- 12.26ml, p < 0.0001). With the software, Investigator B used significantly less contrast medium than Investigator A (p = 0.0468). The DCR software is not accompanied by increased radiation exposure for the patients or the teams. On the contrary, the dose area product was reduced by both investigators but was significantly reduced with DCR in the highly experienced investigator (Investigator A: –DCR 2415.25 +/- 1413.30 cGycm² vs. +DCR 1727.17 +/- 1148.69 cGycm², p = 0.0284). Fluoroscopy time was not different between investigators. Procedural success was 100%. Serious in-hospital adverse events were not observed. One patient of Investigator A suffered from post-procedural acute kidney injury in the –DCR group. Conclusion(s): DCR significantly reduces contrast medium use during PCI irrespective of the investigator’s experience level. Efficacy and safety do not differ between investigators’ experience levels. Whether these excellent results can also be translated into more complex lesion settings has to be evaluated in future trials.Operating principle of DCRPrimary and secondary endpoints

21 April 2026 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
Raphael PhinicaridesRaphael Phinicarides
Raphael Phinicarides
FJFreya Sophie Jenkins
Freya Sophie Jenkins
VHVincent Hendrik Hettlich
Vincent Hendrik Hettlich
CBCharlotte Boettger
Charlotte Boettger
FVFabian Voß
Fabian Voß
UBUdo Boeken
Udo Boeken
Background: Temporary mechanical circulatory support (tMCS) is increasingly used to stabilize patients in cardiogenic shock as a bridge-to-transplant (BTT). While this strategy facilitates listing and organ allocation in critically ill patients, its effect on post-transplant outcomes remains incompletely defined. Methods: We conducted a single-center retrospective cohort study including all adult patients undergoing orthotopic heart transplantation (HTX) between September 2010 and December 2024. Patients were stratified by presence or absence of tMCS at the time of transplant. Primary endpoints were resternotomy, perioperative extracorporeal life support (ECLS), in-hospital mortality, and one-year mortality. Student’s t-test and Chi-square tests were used for comparisons. Results: Among 296 patients (mean age 55.2 ± 10.8 years; 70.6% male), 15 (5.1%) received tMCS at the time of HTX. Compared to controls, tMCS patients had significantly higher inflammatory markers and lower platelet and hemoglobin levels preoperatively. They were more often listed with high urgency (78.6% vs. 39.4%, p<0.01), required perioperative ECLS more frequently (64.3% vs. 26.9%, p<0.01), and exhibited higher in-hospital (21.4% vs. 7.6%, p<0.01) and one-year mortality (54.5% vs. 16.7%, p<0.01). Resternotomy rates were similar. Patients bridged with Impella or transitioned from ECMO to RVAD had better outcomes than those transplanted directly from ECLS. Conclusion: HTX in tMCS-supported patients is feasible but associated with significantly higher early and mid-term mortality. The type of preoperative support and transition strategy may impact outcomes. Tailored bridging concepts and early conversion to durable or RVAD-based support warrant further investigation.

16 April 2026 in Zeitschrift für Herz-,Thorax- und Gefäßchirurgie
Verified
Journal Article
Closed access
PDF file
Raphael PhinicaridesRaphael Phinicarides
Raphael Phinicarides
UBUdo Boeken
Udo Boeken
ACAngelika Costard-Jäckle
Angelika Costard-Jäckle
JGJan Gummert
Jan Gummert
ALArtur Lichtenberg
Artur Lichtenberg
RSRene Schramm
Rene Schramm

28 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
Raphael PhinicaridesRaphael Phinicarides
Raphael Phinicarides
KKKathrin Klein
Kathrin Klein
CJChristian Jung
Christian Jung
BFBernardo S. Franklin
Bernardo S. Franklin
IHIbrahim Hawwari
Ibrahim Hawwari
TZTobias Zeus
Tobias Zeus
Background: Calcific aortic stenosis (AS) is one of the most common and prognostically relevant valvular heart diseases, with a growing global burden driven by population ageing. Prediction of disease progression from moderate to severe AS, which would be instrumental for earlier diagnosis and treatment, remains challenging. At the same time, moderate AS is increasingly recognized as a heterogeneous condition associated with clinically relevant risk, particularly in patients with cardiac damage, heart failure, or rapid disease progression. Conventional echocardiographic parameters incompletely capture the biological heterogeneity underlying AS progression. The MODAS study was established to investigate biomarkers and mechanisms of AS progression and outcome using longitudinal multimodal phenotyping. Methods: The MODAS Study is a prospective, multicenter, longitudinal observational cohort study enrolling adults with moderate calcific tricuspid AS at three tertiary heart valve centers in Germany. Participants undergo standardized baseline assessment including clinical phenotyping, laboratory testing, electrocardiography, transthoracic echocardiography, cardiac computed tomography and cardiac magnetic resonance imaging. Biospecimens are collected for biomarker, immunologic, proteomic, and genetic analyses, including genome-wide association studies and assessment of clonal haematopoiesis. Participants are followed annually for up to 5 years with repeat clinical assessment, laboratory testing, and echocardiography. The primary endpoint is time to progression to severe AS according to 2025 ESC/EACTS guideline criteria or aortic valve replacement for severe AS, adjudicated by the local multidisciplinary Heart Team. Secondary endpoints include all-cause mortality and additional clinical outcome trajectories. Multimodal data integration will be used to develop and validate prediction models for disease progression and outcome. Discussion: The MODAS Study will provide a harmonized, deeply phenotyped longitudinal dataset to improve risk stratification in moderate AS and to identify imaging, inflammatory, and genetic markers associated with rapid progression and adverse outcomes. The study is designed to support future personalized surveillance strategies, improved selection for earlier intervention, and mechanistic understanding of calcific AS progression. Trial registration: ClinicalTrials.gov NCT05851209 . Registered on 9 May 2023.